Allowing simultaneous Rx and OTC sales of the same drug, a part of a US proposed rule for facilitating OTC switches, could help pharma firms “have the best of both worlds” but also could become a disincentive for investing in preparing applications to move ingredients to nonprescription.
In a separate reference in its recent notice on preparing applications for OTC distribution of naloxone, the Food and Drug...